Strongbridge Biopharma plc to Host First Quarter 2021 Financial Results Conference Call on May 12, 2021
Strongbridge Biopharma plc (Nasdaq: SBBP) will host a conference call on May 12, 2021, at 8:30 a.m. ET to discuss its first quarter 2021 financial results and corporate highlights. The call will follow the release of financial results earlier that day. Interested parties can access the call by dialing (844) 285-7153 (domestic) or (478) 219-0180 (international) using conference ID 9478726. A replay will be available for one week after the call. Strongbridge focuses on therapies for rare diseases, including RECORLEV® and KEVEYIS®, with orphan drug designations.
- Focus on rare disease therapies indicates a niche market potential.
- RECORLEV® and KEVEYIS® have received orphan drug designation from FDA and EMA.
- None.
DUBLIN, Ireland and TREVOSE, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on May 12, 2021 at 8:30 a.m. ET to discuss the Company’s first quarter 2021 financial results and corporate highlights. The conference call will follow the anticipated release of the Company’s financial results earlier that day.
Event Details
Strongbridge will host a conference call on Wednesday, May 12, 2021 at 8:30 a.m. ET. To access the live call, dial (844) 285-7153 (domestic) or (478) 219-0180 (international) with conference ID 9478726. The conference call will also be webcast from the Company’s website at www.strongbridgebio.com under the “Investor/Webcasts and Presentations” section. A replay of the call will be made available for one week following the conference call. To hear a replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) with conference ID 9478726.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
Contacts:
Corporate & Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
Solebury Trout
Mike Biega
+1 617-221-9660
mbiega@soleburytrout.com
FAQ
When will Strongbridge Biopharma release its Q1 2021 financial results?
What is the conference call ID for Strongbridge's Q1 2021 results call?
How can I access the Strongbridge Q1 2021 financial results conference call?
What is the focus of Strongbridge Biopharma?
